OR WAIT 15 SECS
Volume 14, Issue 6
Intertek has announced the expansion of its pharmaceutical services laboratory in Melbourn, near Cambridge, UK, through the acquisition of a new 20,000 sq. ft facility.
Intertek, a provider of total quality assurance, has announced the expansion of its pharmaceutical services laboratory in Melbourn, near Cambridge, United Kingdom, through the acquisition of a new 20,000 sq. ft facility.
The new facility doubles the current footprint of the company’s laboratory and is under development. The newly expanded facility is expected to open towards the end of 2019 and should provide capacity for more than 100 additional employees, which the company will recruit over a four-year period, it was revealed in a May 1, 2019 press release.
This new facility is located adjacent to the company’s current good manufacturing practice (GMP) laboratory and will expand the inhalation and nasal testing resources. Additionally, it will provide a dedicated laboratory space that will focus on formulation development of inhaled biologics aimed at meeting the increasing demand from global clients.
“We are delighted to expand and invest in inhalation and nasal product testing for biologics and pharmaceuticals at our Melbourn site, as global demand grows for specialist contract laboratory services,” said Intertek UK & Eire chief executive Rob van Dorp. “This latest expansion brings increased capacity and flexibility and will help to deliver a superior customer service for our clients around the world. Integrated with the teams’ outstanding expertise in analytical and formulation support for the pharmaceutical, biotechnology, and drug delivery industries, we can effectively help our clients to meet milestones for their challenging pharmaceutical development programmes through our systemic, end-to-end Total Quality Assurance solutions.”